Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals
Acquisition of Metys broadens Novaremed's pipeline focused on novel, non-opioid development candidates for chronic pain indications with the addition of two complementary development projects
Expansion of pipeline allows Novaremed to target a wider segment of neuropathic pain indications, adding chemotherapy-induced peripheral neuropathy (CIPN) to its current focus on painful diabetic peripheral neuropathy (PDPN)
Transaction significantly advances Novaremed's strategy to emerge as a leading Company in the non-opioid pain management space
Election of Andrew J. Oakley to the Board of Directors of Novaremed strengthens leadership team
Novaremed AG, a privately held clinical-stage b
